Biotech's stock offering to fund work on stem cell product

08/15/2013 | San Diego Union-Tribune · Xconomy

Fate Therapeutics could secure as much as $69 million from an initial public offering, according to an SEC filing. The San Diego-based firm plans to use the money to further develop ProHema, its umbilical cord blood-based product designed to enhance the success of hematopoietic stem cell transplants, and other preclinical-stage products.

View Full Article in:

San Diego Union-Tribune · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN